Patents by Inventor Edward F. Plow

Edward F. Plow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7122324
    Abstract: Diagnostic systems, methods, polypeptides and antibodies for detecting the presence of C-terminal hGPIIb fragment of the platelet receptor GPIIb-IIIa in a body fluid sample are disclosed.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: October 17, 2006
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Andrew L. Frelinger, III, Edward F. Plow
  • Patent number: 6787320
    Abstract: Diagnostic systems, methods, polypeptides and antibodies for detecting the presence of C-terminal hGPIIb fragment of the platelet receptor GPIIb-IIIa in a body fluid sample are disclosed.
    Type: Grant
    Filed: October 4, 2001
    Date of Patent: September 7, 2004
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Andrew L. Frelinger, III, Edward F. Plow
  • Publication number: 20020177173
    Abstract: Diagnostic systems, methods, polypeptides and antibodies for detecting the presence of C-terminal hGPIIb fragment of the platelet receptor GPIIb-IIIa in a body fluid sample are disclosed.
    Type: Application
    Filed: October 4, 2001
    Publication date: November 28, 2002
    Applicant: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Andrew L. Frelinger, Edward F. Plow
  • Patent number: 6323324
    Abstract: Diagnostic systems, methods, polypeptides and antibodies for detecting the presence of C-terminal hGPIIb fragment of the platelet receptor GPIIb-IIIa in a body fluid sample are disclosed.
    Type: Grant
    Filed: May 16, 2000
    Date of Patent: November 27, 2001
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Andrew L. Frelinger, III, Edward F. Plow
  • Patent number: 6316412
    Abstract: Novel polypeptides derived from human fibronectin are described which bind to integrin receptors expressed by cells. The receptor binding site of human fibronectin begins at amino acid residue 1394 and ends at residue 1400 of fibronectin. The polypeptides facilitate attachment of cells to substrates either alone or in conjunction with RGD-containing peptides. Vectors, fusion proteins and antibodies are also described. Methods for promoting cell attachment and for inhibiting cell adhesion are also described.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: November 13, 2001
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Edward F. Plow, Ronald Bowditch
  • Patent number: 6063907
    Abstract: Antibodies for detecting the presence of C-terminal hGPIIb fragment of the platelet receptor GPIIb-IIIa in a body fluid sample are disclosed.
    Type: Grant
    Filed: February 10, 1998
    Date of Patent: May 16, 2000
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Andrew L. Frelinger, III, Edward F. Plow
  • Patent number: 5843774
    Abstract: Novel polypeptides derived from human fibronectin are described which bind to integrin receptors expressed by cells. The receptor binding site of human fibronectin begins at amino acid residue 1394 and ends at residue 1400 of fibronectin. The polypeptides facilitate attachment of cells to substrates either alone or in conjunction with RGD-containing peptides. Vectors, fusion proteins and antibodies are also described. Methods for promoting cell attachment and for inhibiting cell adhesion are also described.
    Type: Grant
    Filed: February 25, 1997
    Date of Patent: December 1, 1998
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Edward F. Plow, Ronald Bowditch
  • Patent number: 5773574
    Abstract: Novel polypeptides derived from human fibronectin are described which bind to integrin receptors expressed by cells. The receptor binding site of human fibronectin begins at amino acid residue 1394 and ends at residue 1400 of fibronectin. The polypeptides facilitate attachment of cells to substrates either alone or in conjunction with RGD-containing peptides. Vectors, fusion proteins and antibodies are also described. Methods for promoting cell attachment and for inhibiting cell adhesion are also described.
    Type: Grant
    Filed: November 27, 1991
    Date of Patent: June 30, 1998
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Edward F. Plow, Ronald Bowditch
  • Patent number: 5763580
    Abstract: Diagnostic systems, methods, polypeptides and antibodies for detecting the presence of C-terminal hGPIIb fragment of the platelet receptor GPIIb-IIIa in a body fluid sample are disclosed.
    Type: Grant
    Filed: January 26, 1994
    Date of Patent: June 9, 1998
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Andrew L. Frelinger, III, Edward F. Plow
  • Patent number: 5492890
    Abstract: Novel polypeptides derived from human fibronectin, and fusion proteins containing those peptide sequences are described which define a receptor binding site on fibronectin that binds to the platelet receptor glycoprotein GPIIb-IIIa expressed by cells. The receptor binding site of human fibronectin includes at least fibronectin amino acid residues 1410-1436. The polypeptides facilitate attachment of cells to substrates either alone or in conjunction with RGD-containing peptides. Vectors preparing the fusion proteins and antibodies are also described. Methods for promoting cell attachment and for inhibiting cell adhesion are also described.
    Type: Grant
    Filed: December 5, 1991
    Date of Patent: February 20, 1996
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Edward F. Plow, Ronald Bowditch
  • Patent number: 5473051
    Abstract: The present invention contemplates therapeutic compositions containing a D.sub.30 homolog capable of binding to the Mac-1 receptor D.sub.30 binding site and inhibiting fibrinogen binding to the Mac-1 receptor via the D.sub.30 binding site, Methods of inhibiting Mac-1 receptor binding to any Mac-1 ligand and methods of inhibiting Mac-1 receptor mediated inflammation within a patient by administering a D.sub.
    Type: Grant
    Filed: July 18, 1991
    Date of Patent: December 5, 1995
    Assignee: The Scripps Research Institute
    Inventors: Dario C. Altieri, Edward F. Plow, Thomas S. Edgington
  • Patent number: 5470738
    Abstract: An antibody that immunoreacts with a ligand-induced binding site (LIBS) on GPIIIa, and particularly, a LIBS induced in a platelet-associated GPIIb-IIIa/fibrinogen complex is disclosed. Further disclosed are diagnostic systems and methods for assaying LIBS-containing platelets in a vascular fluid sample using the antibodies of the invention.
    Type: Grant
    Filed: October 4, 1993
    Date of Patent: November 28, 1995
    Assignee: The Scripps Research Institute
    Inventors: Andrew L. Frelinger, III, Edward F. Plow, Mark H. Ginsberg
  • Patent number: 5399481
    Abstract: The present invention discloses polypeptides consisting essentially of an amino acid residue sequence corresponding to a formula selected from the group consisting of: Tyr-His-Asp-Arg-Lys-Glu-Phe-Ala-Lys-Phe-Glu-Glu-Glu-Arg-Ala-Arg-Ala-Lys-Tr p-Asp-Thr-Ala-Asn-Asn (SEQ ID NO 1); Ala-Asn-Asn-Pro-Leu-Tyr-Lys-Glu-Ala-Thr-Ser-Thr-Phe-Thr-Asn-Ile-Thr-Tyr-Ar g-Gly-Thr (SEQ ID NO 2); Ile-His-Asp-Arg-Lys-Glu-Phe-Ala-Lys-Phe-Glu-Glu-Glu-Arg-Ala-Arg-Ala-Lys-Tr p-Asp-Thr-Ala-Asn-Asn-Pro-Leu-Tyr-Lys-Glu-Ala-Thr-Ser-Thr-Phe-Thr-Asn-Ile-T hr-Tyr-Arg-Gly-Thr (SEQ ID NO 4); and Gly-Pro-Asp-Ile-Leu-Val-Val-Leu-Leu-Ser-Val-Met-Gly-Ala-Ile-Leu-Leu-Thr-Gl y-Leu-Ala-Ala-Leu-Leu-Ile-Trp-Lys-Leu-Leu-Ile-Thr-Ile-His-Asp-Arg-Lys-Glu-P he-Ala-Lys-Phe-Glu-Glu-Glu-Arg-Ala-Arg-Ala-Lys-Trp-Asp-Thr-Ala-Asn-Asn-Pro- Leu-Tyr-Lys-Glu-Ala-Thr-Ser-Thr-Phe-Thr-Asn-Ile-Thr-Tyr-Arg-Gly-Thr (SEQ ID NO 5), as well as diagnostic kits including same.
    Type: Grant
    Filed: December 29, 1992
    Date of Patent: March 21, 1995
    Assignee: The Scripps Research Institute
    Inventors: Robert McMillan, Mark H. Ginsberg, Edward F. Plow
  • Patent number: 5391704
    Abstract: A polypeptide consisting essentially of an amino acid residue sequence corresponding to a formula selected from the group consisting of:Tyr-His-Asp-Arg-Lys-Glu-Phe-Ala-Lys-Phe-Glu-Glu-Glu-Arg-Ala-Arg-Ala-Lys-Trp -Asp-Thr-Ala-Asn-Asn; andAla-Asn-Asn-Pro-Leu-Tyr-Lys-Glu-Ala-Thr-Ser-Thr-Phe-Thr-Asn-Ile-Thr-Tyr-Arg -Gly-Thr.
    Type: Grant
    Filed: November 27, 1991
    Date of Patent: February 21, 1995
    Assignee: The Scripps Research Institute
    Inventors: Robert McMillan, Mark H. Ginsberg, Edward F. Plow
  • Patent number: 5372933
    Abstract: Receptor-induced binding sites (RIBS) expressed in a ligand when that ligand is bound in a complex with a receptor are disclosed, as are polypeptides that correspond in amino acid residue sequence with a RIBS expressed by a receptor-ligand complex. Particularly-preferred polypeptides correspond to a RIBS amino acid sequence of the gamma chain of human fibrinogen. Monoclonal antibodies that immunoreact with a RIBS but do not substantially immunoreact with either the ligand or the receptor when free in solution are also disclosed, as are hybridomas secreting those antibodies, and methods of making and using such antibodies.
    Type: Grant
    Filed: February 12, 1991
    Date of Patent: December 13, 1994
    Assignee: The Scripps Research Institute
    Inventors: Concepcion Zamarron, Edward F. Plow, Mark H. Ginsberg
  • Patent number: 5306620
    Abstract: An integrin-activating antibody is disclosed that immunoreacts with an integrin and when immunoreacted increases the binding affinity of the integrin for binding to ligands specific for the integrin. The antibody also immunoreacts with a ligand-induced binding site (LIBS) on the integrin when the integrin is specifically bound to its ligand. Further disclosed are therapeutic compositions and methods for promoting cell adhesion using the disclosed integrin-activating antibodies.
    Type: Grant
    Filed: November 13, 1990
    Date of Patent: April 26, 1994
    Assignee: The Scripps Research Institute
    Inventors: Mark H. Ginsberg, Timothy E. O'Toole, Edward F. Plow, Andrew L. Frelinger, III
  • Patent number: 5284751
    Abstract: An antibody that immunoreacts with a ligand-induced binding site (LIBS) on GPIIIa, and particularly, a LIBS induced in a platelet-associated GPIIb-IIIa/fibrinogen complex is disclosed. Further disclosed are diagnostic systems and methods for assaying LIBS-containing platelets in a vascular fluid sample using the antibodies of the invention.
    Type: Grant
    Filed: October 5, 1989
    Date of Patent: February 8, 1994
    Assignee: The Scripps Research Institute
    Inventors: Andrew L. Frelinger, III, Edward F. Plow, Mark H. Ginsberg
  • Patent number: 5262520
    Abstract: Polypeptides derived from the ligand-binding portion of an Integrin alpha subunit are disclosed as are their use for modulation of Integrin ligand binding. Anti-peptide antibodies, hybridomas secreting the antibodies, as well as methods of making and using such antibodies and recombinant DNA molecules coding for the polypeptides are also described. The polypeptides and antibodies to the polypeptides are effective inhibitors of fibrinogen binding to platelets.
    Type: Grant
    Filed: November 29, 1990
    Date of Patent: November 16, 1993
    Assignee: The Scripps Research Institute
    Inventors: Edward F. Plow, Stanley E. D'Souza, Mark H. Ginsberg
  • Patent number: 5204445
    Abstract: Polypeptides which are derived from the Arg-Gly-Asp (RGD) binding portion of an Integrin beta subunit are disclosed as are their use for modulation of Integrin ligand binding. Anti-peptide antibodies, hybridomas secreting these antibodies, as well as methods of making and using such antibodies, and recombinant DNA molecules that define the structural gene coding for the polypeptides are also contemplated as within the scope of the present invention.
    Type: Grant
    Filed: October 2, 1989
    Date of Patent: April 20, 1993
    Assignee: The Scripps Research Institute
    Inventors: Edward F. Plow, Stanley E. D'Souza, Mark H. Ginsberg
  • Patent number: 5196511
    Abstract: Polypeptides which are derived from the ligand-binding portion of an Integrin alpha subunit are disclosed as are their use for modulation of Integrin ligand binding. Anti-peptide antibodies, hybridomas secreting these antibodies, as well as methods of making and using such antibodies, and recombinant DNA molecules that define the structural gene coding for the polypeptides are also contemplated as within the scope of the present invention.
    Type: Grant
    Filed: December 1, 1989
    Date of Patent: March 23, 1993
    Assignee: The Scripps Research Institute
    Inventors: Edward F. Plow, Stanley E. D'Souza, Mark H. Ginsberg